Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. by Płoski, R, Brand, O, Jurecka-Lubieniecka, B, Franaszczyk, M, Kula, D, Krajewski, P, Karamat, M, Simmonds, M, Franklyn, J, Gough, S, Jarząb, B, Bednarczuk, T

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. by Wells, SA, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply by Jr, W, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M

Reply to J.-F. Chatal et al. by Wells Jr, SA, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues by Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K

Get full text